Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC012F in Refractory Systemic Lupus Erythematosus
NCT05858684Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- May 2023
- Primary completion
- Aug 2028
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC012 in systemic lupus erythematosus (SLE), sponsored by Renji Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 12 weeks. Started May 2023; status: recruiting.
02
Drugs
GC012
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05858684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05858684.